MAK OSS FEMORAL KNEE COMPONENTS

K131393 · Biomet Orthopedics Corp. · KRO · Oct 24, 2013 · Orthopedic

Device Facts

Record IDK131393
Device NameMAK OSS FEMORAL KNEE COMPONENTS
ApplicantBiomet Orthopedics Corp.
Product CodeKRO · Orthopedic
Decision DateOct 24, 2013
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3510
Device ClassClass 2
AttributesTherapeutic

Intended Use

The MAK OSS Femoral Knee Components are intended for cemented use only.

Device Story

MAK OSS Femoral Knee Components are optional femoral knee components used with the Orthopedic Salvage System (OSS) for total knee replacement. The device includes resurfacing or segmental femoral components that utilize the OSS yoke and axle to limit knee extension and prevent hyperextension. The subject device features a modified locking pin design with reduced diameter and added locking tabs. The device is intended for use by orthopedic surgeons in clinical settings. It is implanted to restore joint function and stability in patients with severe joint disease, trauma, or tumor-related bone loss. The locking pin modification ensures secure component fixation. The device benefits patients by providing a constrained, stable knee joint replacement option.

Clinical Evidence

No clinical data. Substantial equivalence was demonstrated through bench testing (verification of insertion and extraction forces).

Technological Characteristics

Femoral knee components featuring a modified locking pin made of wrought Co-Cr-Mo alloy (ASTM F-1537). The pin is 0.002 inches smaller in diameter than the predicate and includes integrated locking tabs. The system is a constrained, cemented prosthesis (KRO).

Indications for Use

Indicated for patients requiring total knee replacement due to painful/disabled joints from avascular necrosis, osteoarthritis, rheumatoid arthritis, or traumatic arthritis; correction of varus, valgus, or post-traumatic deformity; revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement; ligament deficiencies; tumor resections; treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur; or trauma. When used with the Compress Segmental Femoral Replacement System, indicated for correction/revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement; tumor resections; revision of failed total joint arthroplasty; and trauma.

Regulatory Classification

Identification

A knee joint femorotibial metal/polymer constrained cemented prosthesis is a device intended to be implanted to replace part of a knee joint. The device limits translation or rotation in one or more planes and has components that are linked together or affined. This generic type of device includes prostheses composed of a ball-and-socket joint located between a stemmed femoral and a stemmed tibial component and a runner and track joint between each pair of femoral and tibial condyles. The ball-and-socket joint is composed of a ball at the head of a column rising from the stemmed tibial component. The ball, the column, the tibial plateau, and the stem for fixation of the tibial component are made of an alloy, such as cobalt-chromium-molybdenum. The ball of the tibial component is held within the socket of the femoral component by the femoral component's flat outer surface. The flat outer surface of the tibial component abuts both a reciprocal flat surface within the cavity of the femoral component and flanges on the femoral component designed to prevent distal displacement. The stem of the femoral component is made of an alloy, such as cobalt-chromium-molybdenum, but the socket of the component is made of ultra-high molecular weight polyethylene. The femoral component has metallic runners which align with the ultra-high molecular weight polyethylene tracks that press-fit into the metallic tibial component. The generic class also includes devices whose upper and lower components are linked with a solid bolt passing through a journal bearing of greater radius, permitting some rotation in the transverse plane, a minimal arc of abduction/adduction. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for Biomet Manufacturing Corp. The logo consists of the word "BIOMET" in a stylized font, with the words "MANUFACTURING CORP." printed below. The logo is black and white. ## 510(k) Summary Preparation Date: Applicant/Sponsor: 17 October, 2013 Biomet Manufacturing Corp. 56 East Bell Drive Warsaw, IN 46582 FDA Registration #: 1825034 Contact Person: Gary Baker Sr. Regulatory Specialist 56 East Bell Drive Warsaw, IN 46582 574-267-6639 Ext. 1568 574-371-1027 garv.baker(@biome1.com Proprietary Name: Common Name: . Rotating Hinged Knee MAK OSS Femoral Knee Components Classification Code(s)/Name(s): KRO 888.3510 (KRO) - Knee joint femorotibial metal/polymer constrained cemented prosthesis # Legally Marketed Devices To Which Substantial Equivalence Is Claimed: K083779 - MAK OSS Femoral Knee Components (Biomet) K123501 - Orthopedic Salvage System (Biomet) ## Device Description: The MAK OSS Femoral Knee Components are intended to be used as an optional femoral knee component for use in coniunction with the cleared Orthopedic Salvage System. The MAK OSS Femoral Knee Components include either resurfacing or segmental femoral components that utilize the yoke and axle of the OSS System but limit extension of the knee to limit or prevent hyperextension. ## Intended Use: The MAK OSS Femoral Knee Components are intended for cemented use only. Mailing Address: P.O Box 587 Warsaw, IN 46581-0587 Toll Free. 800.348 9500 Office: 574 267.6639 Main Fax: 574 267.8137 www.biomet.com Shipping Address: 56 East Bell Drive Warsaw, IN 46582 OCT 24 2013 {1}------------------------------------------------ # Indications For Use: Biomet's MAK OSS Femoral Knee Components are intended for use in conjunction with the OSS System for total knee replacement procedures. Specific indications for the OSS System are: - 1. Painful and disabled joint resulting from avascular necrosis, osteoarthritis, rheumatoid arthritis, or traumatic arthritis. - 2. Correction of varus, valgus or post-traumatic deformity. - 3. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. - 4. Ligament deficiencies. - 5. Tumor resections. - 6. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques. * - 7. Revision of previously failed total joint arthroplasty. - 8. Trauma. These devices are to be used with bone cement unless a proximal femur is indicated for use (USA). *Not applicable to Regenerex Ultra Porous Construct titanium knee augment usage (not licensed in Canada), or any other knee component. When components of the Orthopedic Salvage System are used with Biomet's Compress Segmental Femoral Replacement System, they are intended for uncemented application and indicated for: - I. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. - 2. Tumor resections. - 3. Revision of previously failed total joint arthroplasty. - 4. Trauma. ## Proposed Change(s): This Traditional 510(k) is being submitted for design modifications made to the cleared Biomet MAK OSS Femoral Knee Components locking pin. ## Technological Characteristics: The modified MAK OSS locking pin is manufactured from the same wrought Co-Cr-Mo alloy conforming to ASTM F-1537 as the predicate MAK OSS locking pin. The pin diameter has been reduced by 0.002 inches and is longer than the predicate pin. It incorporates tabs to lock the pin in place. No other changes to the MAK OSS components are proposed by this submission. The intended use and the indications for use are identical to the predicate Systems. {2}------------------------------------------------ # Non-Clinical Testing: Verification testing was conducted to demonstrate that the design modification made to the locking pin would not adversely affect the insertion or extraction of the locking pin. The testing demonstrated that the locking pins could be easily inserted and still maintained adequate extraction force. # Clinical Testing: Clinical testing was not required to demonstrate substantial equivalence of the design modifications proposed to the cleared predicate devices. All trademarks are property of Biomet, Inc. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle or bird-like symbol with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the symbol. The logo is black and white. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 October 24, 2013 Biomet Orthopedics Corporation Mr. Gary Baker Senior Regulatory Specialist 56 East Bell Drive Warsaw, Indiana 46582 Re: K131393 Trade/Device Name: MAK OSS Femoral Knee Components Regulation Number: 21 CFR 888.3510 Regulation Name: Knee joint femorotibial metal/polymer constrained cemented prosthesis Regulatory Class: Class II Product Code: KRO Dated: July 30, 2013 Received: August 2, 2013 Dear Mr. Baker: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA 's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set {4}------------------------------------------------ ## Page 2 - Mr. Gary Baker forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/definil.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, # Ering Keith for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ ## Indications for Use 510(k) Number (if known): __K131393 Device Name: MAK OSS Femoral Knee Components #### Indications For Use: Biomet's MAK OSS Femoral Knee Components are intended for use in conjunction with the OSS System for total knee replacement procedures. Specific indications for the OSS System are: - 1. Painful and disabled joint resulting from avascular necrosis, osteoarthritis, rheumatoid arthritis, or traumatic arthritis. - 2. Correction of varus, valgus or post-traumatic deformity. - 3. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. - 4. Ligament deficiencies. - 5. Tumor resections. - 6. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques. * - 7. Revision of previously failed total joint arthroplasty. - 8. Trauma. These devices are to be used with bone cement unless a proximal femur is indicated for use (USA). * Not applicable to Regenerex Ultra Porous Construct titanium knee augment usage (not licensed in Canada), or any other knee component. When components of the Orthopedic Salvage System are used with Biomet's Compress Segmental Femoral Replacement System, they are intended for uncemented application and indicated for: 1. Correction or revision of unsuccessful osteotomy, arthrodesis, or previous joint replacement. - 2. Tumor resections. - 3. Revision of previously failed total joint arthroplasty. - 4. Trauma. Over-The-Counter Use_ NO_ ____(Part 21 CFR Prescription Use YES 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Casey L. Hanley, Ph.D. Division of Orthopedic Devices Page 1 of 1
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%